saredutant
Small moleculeexperimental
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
13
Phase 3
13
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00256113)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Neurokinin 2 receptorANTAGONIST
Neurokinin 2 receptor antagonist
- Neurokinin 2 receptorINHIBITOR
TACR2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)NC1(c2ccccc2)CCN(CC[C@H](CN(C)C(=O)c2ccccc2)c2ccc(Cl)c(Cl)c2)CC1- Mol. weight
- 552.55 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL308148 ↗
Also known as
- saredutant
- saredutant
- saredutant
- saredutant
- saredutant succinate
- (s)-n-methyl-n(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide
- sr 48965
- sr48968
- sr 48968
- sr-48968
- sr48968c
- sr 48968c
- sr-48968c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00629551 | Phase 3 | Feb 1, 2008 | Sanofi |
| NCT00531622 | Phase 3 | Sep 1, 2007 | Sanofi |
| NCT00429260 | Phase 3 | Jan 1, 2007 | Sanofi |
| NCT00417118 | Phase 3 | Dec 1, 2006 | Sanofi |
| NCT00415142 | Phase 3 | Dec 1, 2006 | Sanofi |
| NCT00390650 | Phase 3 | Oct 1, 2006 | Sanofi |
| NCT00390533 | Phase 3 | Sep 1, 2006 | Sanofi |
| NCT00336713 | Phase 3 | May 1, 2006 | Sanofi |
| NCT00250653 | Phase 3 | May 1, 2005 | Sanofi |
| NCT00250601 | Phase 3 | Apr 1, 2005 | Sanofi |
| NCT00250614 | Phase 3 | Apr 1, 2005 | Sanofi |
| NCT00256113 | Phase 3 | Dec 1, 2004 | Sanofi |
| NCT00250627 | Phase 3 | Dec 1, 2004 | Sanofi |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 13 | 13 | 1 | 2004 |
1 organizations
Page 1 / 1